Results 61 to 70 of about 904 (106)

Frequency of Sensitization to Aeroallergens in Patients with Seasonal and Perennial Allergic Conjunctivitis

open access: yesRevista Alergia México, 2014
Background: Allergic conjunctivitis is an in ammatory disease which involves the conjunctiva, its physiopathology is a type I hypersensitivity (IgE mediated). It is related to the sensitization to indoors and out- doors aeroallergens.
Guillermina Cortés-Morales   +3 more
doaj   +1 more source

Phenotypes and clinical outcomes in children with moderate‐to‐severe atopic dermatitis across diverse ancestries: a Spanish multicenter observational study and cluster analysis (AD‐SKINS Project)

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Atopic dermatitis (AD) has a highly variable clinical phenotype and ancestry can contribute to this heterogeneity. This study aims to identify clinical phenotypes of AD in children from diverse ancestry groups, evaluate clinical outcomes and response to treatment, and define phenotypic clusters with potential relevance.
Eugeni Prat‐Colilles   +21 more
wiley   +1 more source

Clinical effectiveness of olopatadine therapy in children with allergic conjunctivitis

open access: yesNational Journal of Physiology, Pharmacy and Pharmacology, 2017
Background: Olopatadine hydrochloride is one of the most promising agents with a broad range of pharmacological effects. It has both antihistaminic and mast cell stabilizing properties. It is used in various allergic diseases, and its ophthalmic solution
Scandashree K   +3 more
doaj   +1 more source

Inborn errors of immunity in children with neuroinflammation

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Inborn errors of immunity (IEIs), an expanding group of monogenic disorders with diverse clinical manifestations, are increasingly recognized to include neuroinflammatory disease. Examples of diseases included under this umbrella are Aicardi–Goutières syndrome, deficiency of adenosine deaminase 2, familial haemophagocytic lymphohistiocytosis ...
Eppie M Yiu   +5 more
wiley   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo   +11 more
wiley   +1 more source

Beyond the Kidney and Lung: Cutaneous and Mucosal Clues to Human Hantavirus Disease

open access: yesInternational Journal of Dermatology, EarlyView.
Rodent exposure and aerosolized excreta can lead to hantavirus infection with systemic endothelial injury and capillary leak, resulting in thrombocytopenia and syndromes such as HPS/HCPS and HFRS/NE. Early dermatologic and mucosal findings, including flushing, conjunctival injection, petechiae/purpura, and mucosal bleeding, may provide important clues ...
Giuseppe Gallo   +2 more
wiley   +1 more source

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This multicentre, observational cohort study in adults and adolescents with atopic dermatitis found that dupilumab treatment provides a higher probability of achieving the treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4 compared with tralokinumab treatment. Absolute EASI and NRS‐pruritus differences were small among responders.
Lian F. van der Gang   +18 more
wiley   +1 more source

Serum Eosinophil‐Derived Neurotoxin (EDN) as a Biomarker for Treatment Response in Atopic Dermatitis

open access: yes
Clinical &Experimental Allergy, EarlyView.
J. I. Olydam   +3 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta   +4 more
wiley   +1 more source

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies

open access: yesClinical Ophthalmology, 2009
Arthur B Epstein1, Peter T Van Hoven2, Alan Kaufman3, Warner W Carr41North Shore Contact Lens and Vision Consultants, Roslyn Heights, NY, USA; 2Primary Eyecare Group PC, Brentwood, TN, USA; 3Adult Allergy Clinic and the Division of Allergy and Immunology,
Arthur B Epstein   +3 more
doaj  

Home - About - Disclaimer - Privacy